Founded in 1997, ExonHit Therapeutics is a biotech company developing innovative molecular diagnostic tests and therapeutics for Alzheimer’s disease and cancer indications.
ExonHit identifies genes whose splicing variants produce abnormal proteins. Identification of these variants enables us to develop diagnostic tests and new therapeutic targets.
Based in Paris, with an American subsidiary in Gaithersburg, Maryland, ExonHit has been listed on NYSE-Euronext Paris (Alternext: ALEHT) since 2005.
